Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis

Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice

(2021) Furio Colivicchi et al.   Journal of Cardiovascular Medicine

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

(2021) Yajnavalka Banerjee et al.   Expert Opinion On Drug Safety

Lipoprotein(a) and Cardiovascular Diseases　― Revisited ―

(2020) Albert Youngwoo Jang et al.   CIRCULATION JOURNAL

2019 clinical trials in lipid lowering

(2020) David I. Feldman et al.   CURRENT OPINION IN CARDIOLOGY

Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease

(2020) Edward K. Duran et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression

(2020) Walter Masson et al.   Lipids in Health and Disease

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

(2020) Dirk J. Blom et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?

(2020) Michel R. Langlois et al.   Current Cardiology Reports

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

(2020) Gregory A. Roth et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease

(2020) Olga Castañer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study

(2020) Camilla Ditlev Lindhardt Johannesen et al.   BMJ-British Medical Journal

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial

(2019) Yundai Chen et al.   DIABETES OBESITY & METABOLISM

Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels

(2019) Yuki Fujihara et al.   CIRCULATION JOURNAL

Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data

(2019) Larysa Strilchuck et al.   Expert Opinion On Drug Safety

PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk

(2019) Julia Brandts et al.   Current Atherosclerosis Reports

Diagnosis of osteoporosis in statin-treated patients is dose-dependent

(2019) Michael Leutner et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   ATHEROSCLEROSIS

Strategies to Overcome Residual Risk During Statins Era

(2019) Kyoung Im Cho et al.   CIRCULATION JOURNAL

ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand

(2019) Yaling Han et al.   Journal of Clinical Lipidology

Evolving concepts on the management of dyslipidaemia

(2019) Olivier S. Descamps et al.   ACTA CLINICA BELGICA

Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits

(2018) Kyoung Im Cho et al.   CIRCULATION JOURNAL

Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases

(2018) Benoit J. Arsenault et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Unravelling HDL—Looking beyond the Cholesterol Surface to the Quality Within

(2018) Sarina Kajani et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PCSK9 inhibition in the management of familial hypercholesterolemia

(2018) Masatsune Ogura   Journal of Cardiology

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)

(2018) Kwang Kon Koh et al.   Journal of Clinical Lipidology

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

(2018) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment

(2018) Stuart S. Carr et al.   PATHOLOGY

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

(2017) Konstantinos C Koskinas et al.   EUROPEAN HEART JOURNAL

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables

(2017) Theodosios D. Filippatos et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction

(2017) Hua Sun et al.   JOURNAL OF LIPID RESEARCH

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Hypertriglyceridaemia and risk of coronary artery disease

(2017) Željko Reiner   Nature Reviews Cardiology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

(2017) Peter P. Toth et al.   Journal of the American Heart Association

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

(2016) Michel Farnier et al.   ATHEROSCLEROSIS

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial –

(2016) Tamio Teramoto et al.   CIRCULATION JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage

(2016) Yingxu Ma et al.   Lipids in Health and Disease

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

(2015) Dean J. Kereiakes et al.   AMERICAN HEART JOURNAL

Non-high-density lipoprotein cholesterol

(2015) Rutger Verbeek et al.   CURRENT OPINION IN LIPIDOLOGY

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

(2015) Harold Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

(2015) L. Shamseer et al.   BMJ-British Medical Journal

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

(2015) L. Shamseer et al.   BMJ-British Medical Journal

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011

(2014) K. K. Ray et al.   EUROPEAN HEART JOURNAL

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

(2013) et al.   EUROPEAN HEART JOURNAL

Association of Hypertension With Stroke Recurrence Depends on Ischemic Stroke Subtype

(2013) Yilong Wang et al.   STROKE

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

(2011) Uchechukwu K. Sampson et al.   Current Atherosclerosis Reports

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)

(2009) Stephen J. Nicholls et al.   AMERICAN JOURNAL OF CARDIOLOGY